OmniAb (OABI) Stock Analysis & Winston Score

OmniAb is a biotechnology company that helps other drug companies discover new antibody-based medicines. It owns a platform of technologies — including its OmniChicken and OmniRat systems — that use specially engineered animals to generate human-like antibodies, which are proteins the body uses to fight disease. These antibody candidates are then licensed to pharmaceutical and biotech partners who develop them into potential treatments. The company makes money primarily through licensing fees, milestone payments, and royalties tied to its partners' drug development progress. OmniAb operates mainly in the United States and works with a broad network of global pharmaceutical partners, giving it a diversified pipeline it does not have to fund itself. Its moat comes from proprietary transgenic animal platforms that are difficult and expensive to replicate. The main risk is that the company is deeply unprofitable and depends heavily on partners successfully advancing drugs through clinical trials — a process that is slow, uncertain, and largely outside OmniAb's control.